-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Novel Approaches for Gene-Based Therapies:​Targeted Gene Insertion of Factor 9 as a Potential Durable Treatment for Hemophilia B

Program: Scientific Program
Session: Next Generation of Gene-Based Therapies for Bleeding Disorders
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Leah Sabin, PhD

Regeneron Pharmaceuticals, New York, NY

Disclosures: Sabin: Regeneron Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company.

See more of: Next Generation of Gene-Based Therapies for Bleeding Disorders
See more of: Scientific Program
Previous Presentation | Next Presentation >>